Dossier
DT120
Coverage of DT120 in the Nexus archive.
- LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors
A phase III trial of an investigational LSD-based pill (DT120) showed it met primary and key secondary endpoints in treating adults with major depressive disorder, according to Definium Therapeutics. The results suggest potential efficacy for the treatment of depression.
- STAT+: Definium LSD therapy helped patients with major depression in late-stage trial
Definium Therapeutics' LSD therapy (DT120) showed significant improvement in patients with major depression during a Phase 3 trial. Patients experienced a 13.3-point drop on the MADRS depression test at six weeks compared to 5.2 points in the placebo group, with effects maintained at 12 weeks.